Crinetics Pharmaceuticals CRNX 深 滬
等待開盤 09-08 09:30:00 美东时间
84.95
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 84.95
- 總市值 90.13亿
- 52周最高 85.01
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 32.30
- 委 比 0.00%
- 總股本 1.06亿
- 歷史最高 85.01
- 量 比 0
- 振 幅 0.00%
- 歷史最低 10.63
- 每 手 1
- 風險率 16.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Suspends Neutral Rating on Crinetics Pharmaceuticals
Cantor Fitzgerald suspends Neutral rating on Crinetics Pharmaceuticals (NASDAQ:CRNX).
09-02 18:36
Vertex Pharmaceuticals names Jonathan Poole to CFO role
Vertex Pharmaceuticals (VRTX) named Jonathan Poole, its current SVP of Finance, as executive vice president and CFO, effective Jan. 1, 2027, succeeding Charles Wagner. Wagner, currently EVP and chief ...
09-01 21:30
Crinetics nears shareholder vote on Vertex merger
An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July ...
08-14 21:21
Top 3 Health Care Stocks That May Implode In August
As of Aug. 12, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
08-12 20:58
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fu...
08-10 20:49
财报速睇 | Crinetics Pharmaceuticals 2026财年Q2营收0.25亿美元，同比增长2400.0%；归母净利润亏损1.21亿美元，同比亏损扩大4.3%
华盛资讯8月4日讯，Crinetics Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.25亿美元，同比增长2400.0%，归母净利润亏损1.21亿美元，同比亏损扩大4.3%。
08-04 05:54
财报速睇 | Crinetics Pharmaceuticals 2026财年Q2营收0.25亿美元，同比增长2336.3%；归母净利润亏损1.21亿美元，同比亏损扩大4.5%
华盛资讯8月4日讯，Crinetics Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.25亿美元，同比增长2336.3%，归母净利润亏损1.21亿美元，同比亏损扩大4.5%。
08-04 05:42
Crinetics Pharmaceuticals Q2 EPS $(1.14) Beats $(1.24) Estimate, Sales $25.118M Beat $14.840M Estimate
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.24) by 8.06 percent. This is a 7.32 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $25.11...
08-04 04:13
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
08-04 03:21
AbCellera inks drug discovery deal with Vertex Pharma
AbCellera (ABCL) on Wednesday announced a collaboration with Vertex Pharmaceuticals (VRTX) to discover and conduct early research into certain T-cell engagers targeting conditions such as autoimmune d...
07-29 22:24
